Li Xiaoxi
Li completed his Ph.D. studies and subsequent postdoctoral training at the Center for Excellence in Molecular Cell Science (CEMCS), Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.
Lecturer in Department of Laboratory Medicine, School of Medicine, Jiangsu University.
Master's Supervisor in Clinical Laboratory Diagnostics
Previous research work (Ph.D. & Postdoc)
1. UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma. Nat Commun 9, 2720 (2018). Link: Nature Communications (2018) 9,2720.
Authorized Patent： ZL201810420761.0 (Mouse model)；ZL201810420763.X (Precision diagnosis)；ZL201810419739.4 (Efficacy evaluation).
2. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Molecular Medicine 7, 438–449 (2015). Link: EMBO Molecular Medicine (2015) 7,438-449.
Clinical trials - China (Update to 202212): CTR20211333-lymphoma-2021、CTR20181208-Hematological Malignancies-2018.
Clinical trials - America and others (Update to 202212): NCT05432375-Glioblastoma-2022, NCT03903458-Malignant Melanoma-2019, NCT03452930-Glioblastoma-2018, NCT03345485-(Small-cell Lung CancerSoft Tissue SarcomaTriple-negative Breast CancerOvarian CancerEndometrial Cancer)-2017, NCT02576496-(Hematological MalignanciesMultiple MyelomaHodgkin's LymphomaCutaneous T Cell Lymphoma)-2015.
Lecturer
Supervisor of Master's Candidates
Alma Mater : CEMCS-SIBCB
Discipline:Clinical Laboratory Diagnostics
Business Address : Room 1221, Building 2, School of Medicine
Contact Information : Email：lixiaoxi@ujs.edu.cn
Email : lixiaoxi@ujs.edu.cn
PostalAddress : 8a6ab1953677964ce950718c46a355d575d470ee8f3db22c9273d502d2142e92308b74be9190159dee4f2aeda6fe4cec727d3a9331116a557b9842b70ead7f3055b7d43eab0b2c229c72cce9e64e6140d5509bb1b71ead839bfb0949cfb136a79caf344084cc96091246aae9f6dc58be20d61548597610cba4a55bb12457a5cc
The Last Update Time : ..
With the aim of developing anti-tumor strategies and novel drug targets discovery of anti-tumor biologics, we will study the mechanism of invasion/metastasis and drug resistance of malignant tumors, design and evaluate synthetic lethal strategies and drug combination regimens, and ultimately enhance the therapeutic effect of anti-tumor drugs, improve the prognosis of patients, and prolong patient survival. In addition, cooperating with other biotech laboratories and biopharmaceutical companies, develop novel biological drugs or therapies, develop and optimize novel animal models of cancer for efficacy evaluation.
